Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications
Meningiomas account for approximately 30% of all new diagnoses of intracranial masses. The 2016 World Health Organization’s (WHO) classification currently represents the clinical standard for meningioma’s grading and prognostic stratification. However, watchful waiting is frequen...
Main Authors: | Riccardo Laudicella, Domenico Albano, Salvatore Annunziata, Diletta Calabrò, Giovanni Argiroffi, Elisabetta Abenavoli, Flavia Linguanti, Antonio Vento, Antonio Bruno, Pierpaolo Alongi, Matteo Bauckneht |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-09-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/11/10/1412 |
Similar Items
-
From the Magic Bullet to Theragnostics: Certitudes and Hypotheses, Trying to Optimize the Somatostatin Model
by: Giuseppe Danilo Di Stasio, et al.
Published: (2021-07-01) -
Clinical Significance of Somatostatin Receptor (SSTR) 2 in Meningioma
by: Wei Wu, et al.
Published: (2020-09-01) -
Unresectable Recurrent Multiple Meningioma: A Case Report with Radiological Response to Somatostatin Analogues
by: Ana Ortolá Buigues, et al.
Published: (2016-08-01) -
Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy
by: Romain Eychenne, et al.
Published: (2020-09-01) -
A Retrospective Interventional Cohort Study to Assess the Safety and Efficacy of Sandostatin LAR for Treatment of Recurrent and/or Refractory Meningiomas
by: Maya Hrachova, et al.
Published: (2020-05-01)